Dr. Nitin Jain, MD

Dr. Jain practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Jain's NPI, 1659459113, was assigned on November 1, 2006. Dr. Jain graduated from All India Institute of Medical Sciences in 2003. Dr. Jain holds Texas license P2463.

Dr. Jain's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Jain's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. Dr. Jain is also affiliated with Memorial Hermann Greater Heights Hospital. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jain practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Jain's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Jain is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Jain's licenses on file in 6 states: Texas, Florida, Michigan, Oklahoma, Illinois and Wisconsin.

Dmand AI lists anemia, atrial fibrillation and flutter, cardiac arrhythmia, chronic anemia, chronic hypertension, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and cirrhosis of the liver among the conditions Dr. Jain treats.

CMS data shows 792 Medicare services from Dr. Jain across 7 procedure codes in 2024, for 254 Medicare patients. Medicare paid $66,810 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 254 Medicare patients who saw Dr. Jain in 2024. The largest group is 65 to 74, with 128 patients. 75% of them have high blood pressure, and 72% have high cholesterol. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jain's median patient age at 72, with 38% women.

In 2024, Dr. Jain wrote 190 Medicare Part D claims for 55 patients. 73% of them were for generic drugs. CMS names the drug for 72 of them, across 3 drugs with 11 or more claims each, at $191,199 in total drug cost. In 2023, CMS named 73 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Jain for performance year 2024, reported as part of a group. Dr. Jain accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 291 papers to Dr. Jain, published from 2007 to 2025. 2021 was the busiest year, with 27. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Leukemia, Lymphocytic, Chronic, B-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma. Dr. Jain has published most often in Am J Hematol. Dr. Jain's most frequent co-authors are Hagop M. Kantarjian, MD, Tapan M. Kadia, MD and Elias J. Jabbour, MD.

Dmand AI links Dr. Jain to 12 clinical trials, 5 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Burkitt Lymphoma and Leukemia. M.D. Anderson Cancer Center sponsors the most, 6. Open Payments lists research payments to Dr. Jain that name 2 trials.

CMS Open Payments shows 314 general payments to Dr. Jain from 32 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 75% of the total. AstraZeneca Pharmaceuticals LP paid the most, $94,010. It also lists 10 research payments totaling $7,412 from 2017 to 2025, naming 2 clinical trials.

Dr. Jain graduated from All India Institute of Medical Sciences in 2003.

Dr. Jain is in network with 6 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 5. Check the plan with the practice before a visit.